The interim president and CEO, David D. Stevens, will remain chairman of the Board. Mr. Palmisano most recently served as president and CEO of ev3, a global endovascular device company, where he was able to triple the company’s market capitalization during his two-year tenure.
The company’s compensation committee of its board of directors has approved a stock option in addition to regular compensation to Mr. Palmisano.
Related Articles on Orthopedic Device Companies:
DJO Global Launches New Technology to Combat Knee Pain
BioMedGPS Launches SmartTRAK Shoulder Recon Module
42 Orthopedic and Spine Devices Receive FDA 510(k) Clearance in August
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.